SCHEMBL902500

SCHEMBL902500

Cc1nc2c(C(=O)NCC3CCCO3)cnn2c(O)c1Cc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.52
LMNA P02545 4/20 0.52
HPGD P15428 5/20 0.50
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
CYP1A2 P05177 3/20 0.50
CYP3A4 P08684 3/20 0.50
CYP2C9 P11712 3/20 0.50
CYP2C19 P33261 3/20 0.50
CYP2D6 P10635 1/20 0.50
TSHR P16473 4/20 0.49
HTT P42858 4/20 0.49
CASP1 P29466 3/20 0.49
CASP7 P55210 3/20 0.49
HSD17B10 Q99714 3/20 0.49
GAA P10253 1/20 0.49
NPSR1 Q6W5P4 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15274737 1.00 TP53 (0.52) TP53LMNAHPGDALDH1A1KDM4E
SCHEMBL902499 1.00 TP53 (0.52) TP53LMNAHPGDALDH1A1KDM4E
SCHEMBL4940751 0.85 HSD17B10 (0.60) TP53LMNAHPGDALDH1A1KDM4E
SCHEMBL4780930 0.84 LMNA (0.64) TP53LMNAHPGDALDH1A1KDM4E
SCHEMBL4725736 0.84 LMNA (0.62) TP53LMNAHPGDALDH1A1KDM4E
SCHEMBL4725441 0.83 KDM4E (0.62) TP53LMNAHPGDALDH1A1KDM4E
SCHEMBL902657 0.81 TP53 (0.60) TP53LMNAHPGDALDH1A1KDM4E
SCHEMBL15572020 0.80 LMNA (0.76) TP53LMNAHPGDALDH1A1KDM4E
SCHEMBL902821 0.80 LMNA (0.64) TP53LMNAHPGDALDH1A1KDM4E
SCHEMBL4940985 0.79 ALDH1A1 (0.64) TP53LMNAHPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 TP53 2371/4885LMNA 4062/4885HPGD 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.